Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH7485 in Advanced Solid Tumors
NCT06487455Phase 1Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Aug 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SPH7485 in solid tumor (advanced stage), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Dose-limiting toxicity at 24 days, Maximum tolerated dose at 24 days and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
SPH7485
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06487455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487455.